2027-A COMPARATIVE EFFICACY OF FIBROSIS-4, LIVER STIFFNESS MEASUREMENT, AND FIBROSCAN-AST SCORE TO PREDICT MAJOR LIVER-RELATED OUTCOMES IN NON-ALCOHOLIC FATTY LIVER DISEASE: AN INTERNATIONAL MULTICENTER STUDY Yu JUN Wong 1,2 , Esteban Urias 3 , Michael W Song 4 , Tanvi Goyal 3 , Wei Xuan Tay 5 , Nicole Xinrong Han 5 , Jing Hong Loo 5 , Tian Yu Qiu 5 , Majd Aboona 6 , Claire Faulkner 6 , Karn Wijarnpreecha 7 , Yiong Huak Chan 8 and Vincent Chen 9 , (1)Department of Gastroenterology & Hepatology, Changi General Hospital, (2)Duke-Nus Medical School, Singhealth, (3)University of Michigan, (4)University of Michigan, Ann Arbor, (5)Changi General Hospital, (6)University of Arizona College of Medicine, Phoenix, AZ, (7)University of Arizona College of Medicine Phoenix, Phoenix, AZ, (8)Yong Loo Lin School of Medicine, National University of Singapore, Singapore, (9)University of Michigan Medical Center Background: Non-invasive tests (NITs) such as FIB-4, liver stiffness measurement (LSM) by vibration controlled transient elastography (VCTE), and FibroscanAST (FAST) are frequently used for risk stratification in non-alcoholic fatty liver disease
Additionally, the DMCB enhanced antioxidant enzyme activities and histologically restored pancreas tissues in diabetic mice
doi: 10.1046/j.1471-4159.2002.01037.x
Interferon-beta promotes macrophage foam cell formation by altering both cholesterol influx and efflux mechanisms
